BRCA1 and cancer: These CpGs were selected based on methylation scores with median methylation level at least 0.01 greater in histologically normal breast tissue of BRCA1/2 mutation carriers (n = 14) compared to cancer-free women with no family or personal history of breast cancer (n = 14), (Fig. 3a) (DNAme Set 1, Materials and Methods).